The GALD.SW stock jumped 7.93% in after-hours trade on 05 Mar 2026 after Galderma Group N released earnings that beat near-term expectations. Shares closed at CHF 155.20, up from a previous close of CHF 143.80, on volume of 458113.00. Investors moved quickly; the stock traded above the 50-day average of CHF 153.84 and well above the 200-day average of CHF 140.03. We summarise results, valuation, and what analysts will watch next in this earnings-focused update

GALD.SW stock: earnings summary and market reaction

Galderma reported results with enough upside to push GALD.SW stock 7.93% higher after-hours on 05 Mar 2026. The company cited strength in Injectable Aesthetics and Dermatological Skincare as the main drivers. Market response lifted the price to CHF 155.20 from CHF 143.80, with intraday range CHF 151.60 to CHF 157.70.

Financials and valuation for GALD.SW stock

On the headline metrics Galderma shows EPS CHF 1.22 and a trailing P/E of 118.69 per the latest quote. Market capitalisation is CHF 34002493914.00 and revenue per share is CHF 19.24. Valuation remains rich: price to sales is 7.46 and price to book is 4.44, which frames expectations for margin expansion or faster growth.

GALD.SW stock outlook: Meyka AI grade and technical signals

Meyka AI rates GALD.SW with a score out of 100: 70.99 (B+), Suggestion: BUY. This grade factors S&P 500 and sector comparison, financial growth, key metrics, forecasts and analyst consensus. Technical indicators show RSI 40.41 and Bollinger upper band CHF 156.24, suggesting short-term momentum is mixed while volume is above average at 458113.00.

What drove the move and segment detail

Management flagged stronger demand in Injectables and Professional Dermatology, which supported the after-hours rally. Guidance commentary pointed to continued pricing power in aesthetics and improving operating leverage in Therapeutic Dermatology. For context, the company trades on SIX in Switzerland and lists product exposure to both prescription and aesthetic channels.

Risks, valuation headwinds and analyst focus for GALD.SW stock

Key risks include the high relative P/E of 118.69, inventory cycles in cosmetic channels, and sensitivity to discretionary spending. Analysts will watch margin progression, free cash flow conversion and any change to buyback or dividend policy. Current net debt to EBITDA is about 2.33, which keeps leverage moderate but requires consistent cash flow.

Trading, liquidity and peer sector context

Liquidity is solid with volume 458113.00 versus average 378303.00, so large flows will move price. In the Consumer Defensive sector, Galderma sits above peers on valuation but below pharmaceutical peers on margins. Investors should compare GALD.SW stock to sector medians on P/E and EV/EBITDA when sizing positions.

Final Thoughts

GALD.SW stock moved materially in after-hours trade on 05 Mar 2026 following earnings that highlighted aesthetics and dermatology strength. The share price at CHF 155.20 reflects both improved growth and a premium valuation, with trailing P/E near 118.69 and price to sales around 7.46. Meyka AI’s forecast model projects a one-year view of CHF 207.05, implying an upside of 33.44% versus the current price; shorter-term quarterly projection is CHF 163.60, a 5.41% upside. Our Meyka grade is 70.99 (B+, BUY) and factors growth, sector comparison, and analyst signals. Given the elevated valuation, prudent investors should watch margin trends, free cash flow and management guidance before adding exposure. For active traders, the technicals point to mixed momentum and above-average liquidity; for long-term holders, the earnings beat supports the growth case but valuation compression remains the main risk. Forecasts are model-based projections and not guarantees. For the full market snapshot see the company page on Meyka and the market note on Investing.com. Meyka AI provides this as AI-powered market analysis to support further research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.